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Abstract
Background and objectives Rapid ultrafiltration rates are associated with adverse outcomes among patients on
hemodialysis. The Centers for Medicare and Medicaid Services is considering an ultrafiltration rate quality
measure for the ESRD Quality Incentive Program. Two measure developers proposed ultrafiltration rate mea-
sures with different selection criteria and specifications. We aimed to compare the proposed ultrafiltration rate
measures and quantify dialysis facility operational burden if treatment times were extended to lower ultrafil-
tration rates.
Design, setting, participants, & measurements Data were taken from the 2012 database of a large dialysis
organization. Analyses of the Centers for Medicare and Medicaid Services measure considered 148,950 patients
on hemodialysis, and analyses of the Kidney Care Quality Alliance measure considered 151,937 patients. We
described monthly patient and facility ultrafiltration rates and examined differences in patient characteristics
across ultrafiltration rate thresholds and differences in facilities across ultrafiltration rate measure scores. We
computed the additional treatment time required to lower ultrafiltration rates ,13 ml/h per kilogram.
Results Ultrafiltration rates peaked in winter and nadired in summer. Patients with higher ultrafiltration rates
were younger; more likely to be women, nonblack, Hispanic, and lighter in weight; and more likely to have
histories of heart failure comparedwith patients with lower ultrafiltration rates. Facilities had, on average, 20.8%
610.3% (July) to 22.8%610.6% (February) of patients with ultrafiltration rates .13 ml/h per kilogram by the
Centers forMedicare andMedicaid Servicesmonthlymeasure. Facilities had, on average, 15.8%68.2%of patients
with ultrafiltration rates $13 ml/h per kilogram by the Kidney Care Quality Alliance annual measure. Larger
facilities (.100 patients) would require, on average, 33 additional treatment hours per week to lower all facility
ultrafiltration rates ,13 ml/h per kilogram when total treatment time is capped at 4 hours.
Conclusions Ultrafiltration rates vary seasonally and across clinical subgroups. Extension of treatment time as a
strategy to lower ultrafiltration rates may pose facility operational challenges. Prospective studies of ultrafil-
tration rate threshold implementation are needed.
Clin J Am Soc Nephrol 11: ccc–ccc, 2016. doi: 10.2215/CJN.13441215
Introduction
Growing evidence supports fluid management as a
critical contributor to outcomes for patients on hemo-
dialysis (HD). Suboptimal fluid management leads to
increased hospitalizations, patient discomfort, and
substantial cost (1–3). However, evidence-based
guidelines are currently lacking. Accurate target
weight estimation and interdialytic weight gain
(IDWG) reduction have proven elusive (3). Fluid re-
moval during dialysis (ultrafiltration [UF]) is a poten-
tially modifiable, facility–controlled aspect of fluid
management. Some experts have advocated for im-
plementation of UF rate ceiling thresholds to reduce
complications from fluid removal practices (4).
The US Centers for Medicare and Medicaid Services
(CMS) is considering a UF rate measure for inclusion
in the 2019 ESRD Quality Incentive Program (QIP).
Before the QIP incorporation, proposed measures are
vetted by technical expert panels and considered for
endorsement by theNational Quality Forum (NQF) (5). In
May of 2015, the NQF considered two UF rate measures
proposed by CMS (measure 2700) and the Kidney Care
Quality Alliance (KCQA; measure 2701) (6). The NQF
endorsed the KCQA measure, but CMS has not finalized
the measure (7). Both UF rate measures assess facility
fluid management by calculating the proportion of pa-
tients with delivered UF rates above specified thresholds
(.13 ml/h per kilogram for the CMS measure and $13
ml/h per kilogram for the KCQA measure). Although
similar in construction and interpretation, the measures
differ in patient selection criteria, time windows, and
number of contributing HD treatments. Neither measure
has provisions for patient subpopulations with plausibly
different UF rate risk thresholds.
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To lower UF rates, dialysis facilities can extend treatment
time (TT) or decrease UF volumes. Both strategies have
important patient and facility implications, and both will
likely be necessary to adequately reduce UF rates. The least
operationally disruptive strategy is intensive dietary coun-
seling to minimize weight gains and thus, obligate UF
volumes. However, dietary counseling is standard in most
nutritional programs, and high weight gains remain com-
mon (8). TT extension will likely be necessary to lower UF
rates for many patients. Using 2012 data from a single
large dialysis organization (LDO), we sought to (1) de-
scribe UF rate distributions and patterns, (2) compare fa-
cilities with higher (versus lower) percentages of patients
with elevated UF rates, and (3) investigate the amount of
additional facility TT required to meet specified UF rate
thresholds.
Materials and Methods
UF Rate Measures
We evaluated the CMS and the KCQA proposed UF rate
measures submitted to the NQF May 2015 multistake-
holder Standing Committee meeting (6). The CMS-proposed
measure was developed in consultation with nephrolo-
gists and measure development experts at the University
of Michigan under the ESRD Quality Measure Develop-
ment, Maintenance, and Support contract. The KCQA-
proposed measure was developed by the KCQA, a dialysis
measure development body supported by Kidney Care
Partners, a multistakeholder coalition that aims to im-
prove care through legislative, regulatory, and quality
initiatives (9).
We analyzed UF rates according to the CMS and the
KCQA measure specifications at the patient and facility
levels using 2012 data from a single LDO (Figure 1, Sup-
plemental Table 1) (6). The UF rate measures reflect the
percentage of patients at a dialysis facility with elevated
UF rates (.13 ml/h per kilogram across all delivered TTs
for the CMS measure and $13 ml/h per kilogram across
delivered TTs ,240 minutes for the KCQA measure). The
measures are reported as proportions (percentages of fa-
cility patients with UF rates above specified thresholds).
Lower scores are more favorable. We also evaluated a
modified KCQA measure, in which we omitted the
TT,240 minutes requirement. In all analyses, delivered
UF rate (milliliters per hour per kilogram) was calculated
by (predialysis weight 2 postdialysis weight [milliliters])/
delivered TT (hours)/postdialysis weight (kilograms).
In primary analyses, monthly CMS UF rate measures
were calculated by dividing the number of facility patients
with UF rates .13 ml/h per kilogram by the total number
of facility patients on HD on a monthly basis. The UF rate
was calculated from the pre- and postdialysis weights and
delivered TT from the HD treatment corresponding to the
day of the monthly clearance assessment. The KCQA mea-
sure was calculated by dividing the total number of facility
patients with an average UF rate $13 ml/h per kilogram
and an average delivered TT ,240 minutes by the total
number of facility patients on HD on a monthly basis. The
KCQA monthly UF rate was computed as a mean of UF
rates from the treatments during the monthly clearance
assessment week. Facility monthly UF rate measure values
were averaged to create an annual measure per the KCQA
specifications. In secondary analyses, we considered alter-
native UF rate calculations by varying data collection days
and the number of treatments contributing to UF rate cal-
culations.
Monthly (CMS) and annual (KCQA) facility UF rate
measure scores were dichotomized at the 75th percentile to
mirror the CMS facility performance evaluation. Facilities
in the highest score quartile had the largest proportion of
patients with UF rates above the specified threshold
compared with lower quartile facilities.
Study Design and Selection Criteria
This study was approved by the University of North
Carolina at Chapel Hill Institutional Review Board. Data were
taken from 196,635 patients from 2449 facilities with available
data in a single LDO’s 2012 database. Cohort entry was dy-
namic and could occur between January 1 and November 30,
2012. Patients entered and exited the cohort and contributed
to different facility monthly cohorts according to selection
criteria application on a rolling monthly basis. This design
mirrors real world measure implementation and facilitates
calculation of monthly proportions of facility patients with
UF rates above proposed thresholds.
Patient eligibility criteria were assessed monthly (Figure
1, Supplemental Table 1). Inclusion criteria for both mea-
sures were patients on HD ages $18 years old and present
at the reporting facility for $30 days. Exclusion criteria for
both measures were patients on peritoneal dialysis or
home HD, patients dialyzing at units with ,11 patients,
and patients with incomplete UF rate data. For the CMS
measure, we excluded patients on dialysis for ,90 days
and patients with reported UF rates ,0 or .50 ml/h per
kilogram. For the KCQA measure, we excluded patients
with less than seven treatments at the facility in the report-
ing month and patients with four or more treatments dur-
ing the weekly calculation period.
Data Collection
Study data were obtained from the LDO’s medical re-
cord. Demographic data were documented at admission to
one of the organization’s facilities. Comorbid conditions
were assessed by the nephrologist at facility admission
and updated on the basis of clinical course. Dialysis ade-
quacy (Kt/V) was measured at least monthly. When more
than one Kt/V measurement was available, the last
monthly value was selected. Treatment variables, includ-
ing pre- and postdialysis weights, delivered TTs, and vas-
cular access type, were recorded every treatment. BP was
measured pre- and postdialysis and at least every 30 min-
utes during HD. Intradialytic hypotension was defined as
nadir intradialytic systolic BP ,90 mmHg in .30% of
treatments in the prior month. Low pre–HD systolic BP
was defined as pre–HD systolic BP ,100 mmHg in .30%
of treatments in the prior month. Facility geographic region
was assigned using US Census designations.
Statistical Analyses
Analyses were performed using SAS, version 9.4 (SAS
Institute Inc., Cary, NC). Patient and facility characteristics
were described as numbers (proportions) for categorical
variables and means6SDs or medians (quartile 1, quartile
3) for continuous variables. UF rate thresholds were
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summarized across the full cohort and across key sub-
groups. Facility characteristics were stratified by region
(western versus nonwestern region). Differences in the
percentage of patients at a dialysis facility with elevated
UF rates across the CMS and the KCQA criteria were com-
pared using paired t tests. Two–tailed P values ,0.05 in-
dicated statistical significance.
To show facility burden resulting from implementation
of the proposed KCQAUF rate threshold, we computed the
additional TT required to lower prescribed UF rates to ,13
ml/h per kilogram. Total TT was capped at 4 hours per the
KCQA specifications. For these analyses, prescribed UF
rate (milliliters per kilogram) was calculated using the for-
mula (predialysis weight from current treatment 2 post-
dialysis weight from previous treatment [milliliters])/
prescribed TT (hours)/postdialysis weight from previous
treatment (kilograms). Supplemental Table 2 shows de-
tailed methods.
Results
Cohort Characteristics
Figure 2 displays patient and facility selection (Figure
2A) and facility locations (Figure 2B). Analyses of the CMS
measure considered 148,950 unique patients from 1902
facilities, and analyses of the KCQA measure considered
151,937 unique patients from 1901 facilities. In the CMS
cohort, the mean age was 62 years old, 36.7% were black,
25.9% had heart failure, and 25.6% dialyzed at facilities in
the western United States as of the first reporting month.
In the KCQA cohort, the mean age was 62 years old, 36.4%
were black, 24.8% had heart failure, and 26.2% dialyzed at
facilities in the western United States as of the first report-
ing month. The cohorts were similar to the broader United
States HD population in terms of age, sex, race, and co-
morbidities (10).
UF Rate Operational Definitions
Patient–level mean UF rates peaked in winter months
and nadired in summer months, ranging from 9.565.3
ml/h per kilogram (July) to 9.965.5 ml/h per kilogram
(February) by the CMS criteria and from 9.565.4 ml/h
per kilogram (July) to 10.065.9 ml/h per kilogram (Febru-
ary) by the KCQA criteria (Table 1, Supplemental Figure
1). Facilities had, on average, 20.8%610.3% (July) to 22.8%
610.6% (February) of patients with UF rates .13 ml/h per
kilogram by the CMS monthly measure. Facilities had, on
average, 15.8%68.2% of patients with UF rates $13 ml/h
per kilogram by the KCQA annual measure. The
Figure 1. | The Centers for Medicare and Medicaid Services (CMS) and the Kidney Care Quality Alliance (KCQA) ultrafiltration (UF) rate
measure specifications and selection criteria. aFor both measures, the UF rate is calculated as UF rate (milliliters per hour per kilogram) =
(predialysis weight 2 postdialysis weight [milliliters])/delivered TT (hours)/postdialysis weight (kilograms). The CMS UF rate measure nu-
merator details are as follows. For the hemodialysis (HD) treatment thatmeets selection criteria, (1) calculate theUF rate (milliliters per hour per
kilogram), and (2) sum the number of patients in each facility with a UF rate .13 ml/h per kilogram. The KCQA UF rate measure numerator
details are as follows. For theHD treatments thatmeet selection criteria, (1) calculate theUF rate (milliliters per hour per kilogram), (2) calculate
each patient’s average UF rate for all HD treatments during the week that the monthly Kt/V is drawn, (3) calculate each patient’s average
treatment time (TT) for all HD treatments during theweek thatmonthly Kt/V is drawn, and (4) sum the number of patients in each facility with an
averageUF rate$13ml/h per kilogram and an average TT,240minutes. bTheNational Quality Forum reported an exclusion of more than four
HD treatments during the calculation period in their documentation of the KCQAmeasure (6); however, the KCQAmeasure developers tested
an exclusion of four or more HD treatments during the calculation period (21). Because an exclusion of four or more HD treatments represents
developer intent and is congruentwith the standard practice of threeweekly treatments, we evaluated themeasure using an exclusion of four or
more HD treatments. PD, peritoneal dialysis.
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proportions of facility patients with monthly UF rates
above measure thresholds differed significantly comparing
the CMS and the KCQA criteria (monthly P values ,0.001)
(Table 1).
Because the CMS measure relies on a single UF rate
value, we performed secondary analyses varying the UF
rate collection day. UF rates calculated from the last
nonmissing monthly UF rate value had the greatest
variation, ranging from 8.765.2 ml/h per kilogram
(June) to 10.365.6 ml/h per kilogram (January). Months
ending in Mondays or Tuesdays (treatment days after the
long interdialytic break) had the highest UF rates. Months
ending in Fridays and Saturdays (treatment days corre-
sponding to the third weekly HD treatment) had the
Figure 2. | The flow diagram shows selection of unique patient Centers for Medicare and Medicaid (CMS) and the Kidney Care Quaility
Alliance (KCQA) cohorts by application of selection criteria on a rolling monthly basis, and the map illustrates the diverse locations of
dialysis facilities included in the analytic cohorts classified by census region. (A) Flow diagram of patient and facility selection on the basis of
the CMS and KCQA ultrafiltration (UF) rate measure specifications and (B) census regions of facilities included in the analytical cohort. HD,
hemodialysis; LDO, large dialysis organization; PD, peritoneal dialysis; TT, treatment time; wt, weight.
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lowest UF rates. Supplemental Table 3 displays differences
across UF rate operational definitions.
Patient and Facility Characteristics across UF Rate Groups
and Thresholds
Patients with UF rates.13 ml/h per kilogram in the first
reporting month were younger; more likely to be women,
nonblack, and Hispanic; and more likely to have histories
of heart failure, lower body weight, greater dialysis vin-
tage, higher predialysis BP, greater IDWG, and shorter TT
compared with patients with lower UF rates. Findings
were consistent across measures and months (Table 2).
Facilities falling in the highest UF measure quartile (facil-
ities with .28.3% of patients with UF rates .13 ml/h per
kilogram by the CMS criteria and facilities with .20.3% of
patients with UF rates $13 ml/h per kilogram by the
KCQA criteria) were more likely to be located in the west-
ern United States, have ,25 patients, have fewer black
patients, and have more Hispanic patients compared
with facilities in lower quartiles (Table 3).
We applied a lower UF rate threshold of 10 ml/h per
kilogram to the full cohort and key subgroups (Supple-
mental Table 4). Among the CMS cohort patients with
heart failure (n=38,506), 24.8% had UF rates .13 ml/h
per kilogram, and 45.4% had rates .10 ml/h per kilogram.
Among patients with histories of intradialytic hypotension
(n=30,045), 20.7% had UF rates .13 ml/h per kilogram,
and 40.5% had rates .10 ml/h per kilogram. Measure and
monthly results were similar.
Facility TT Burden in the Setting of UF Rate Thresholds
Among 103,850 patients in the January 2012 KCQA
cohort, 20,152 (19%) had UF rates $13 ml/h per kilogram.
Figure 3 depicts a single patient’s TT extension over 1
month in response to application of the KCQA UF rate
threshold. To lower UF rates to ,13 ml/h per kilogram
via TT extension (with total TT remaining at $4 hours),
facilities would require a mean additional TT of 17616
h/wk. Larger facilities would require proportionately
more TT compared with smaller facilities, with facilities
with .100 patients requiring an additional 33 h/wk (Fig-
ure 4). Percentages of patients with UF rates remaining
$13 ml/h per kilogram after application of varied TT ex-
tension paradigms are presented in Table 4. Supplemental
Figure 2 displays facility TT burden if TTs were extended
to bring UF rates to ,13 ml/h per kilogram without ap-
plication of a 4-hour total TT maximum.
Discussion
In this study, we examined UF rate patterns and pro-
posed UF rate quality measures and calculated the facility
TT burden with UF rate threshold implementation. Patient
UF rates fluctuated over the course of the year, with the
highest UF rates occurring in winter and the lowest rates
occurring in summer. Patients with higher UF rates were
more likely to be women, nonblack, and Hispanic and have
lower body weight and heart failure. Facilities with higher
percentages of patients with elevated UF rates were more
likely to be located in the western Unites States and have
fewer black and more Hispanic patients compared with
facilities with lower percentages. Extension of TT as a
strategy to reduce UF rates resulted in a mean weekly
facility burden of 17 TT hours when total TTs were capped
at 4 hours.
Existing observational data suggest an association be-
tween higher UF rates and adverse outcomes (11,12). Al-
though these associations have not been prospectively
tested, they are supported by plausible physiologic mech-
anisms, including UF–related end organ ischemia and hy-
pervolemia from hemodynamic instability reactive
measures (13,14). UF rates are determined by the amount
of fluid removed (typically equivalent to IDWG) and HD
duration. Dialysis providers prescribe UF volume and TT,
rendering UF rates within facility control. Reducing UF
volumes to curb UF rates without concurrent IDWG re-
duction would leave patients disadvantageously volume
expanded. Thus, extending TT or adding supplemental
treatments would likely be required to lower UF rates.
However, patients are generally averse to longer TTs
(15), raising concern about patient acceptance and under-
scoring the need for prospective study. Despite these un-
certainties, CMS is considering inclusion of a UF rate
quality measure in the 2019 QIP (7).
The ESRD QIP aims to promote patient health by
providing financial incentive for dialysis facilities to deliver
high-quality care. In this value–based care model, clinical
measures are intended to improve outcomes, reduce dis-
parities, and limit unintended consequences (16). We eval-
uated UF rate patterns and considered different
approaches to measure definition. We found that UF rates
vary over the calendar year. This month to month varia-
tion, plausibly related to seasonal hydration patterns, sug-
gests that a monthly measure, as proposed by CMS, best
captures facility UF rate practices. An annual measure, as
recommended by KCQA, obscures seasonal variation.
Also, we showed that UF rates vary by assessment day,
with greater UF rates occurring after the long interdialytic
break. Mean–based UF rate measures, as proposed by
KCQA, may best capture facility practices and thwart
gaming, a practice made easier by reliance on a single
value. Although single UF rate values are easier to collect,
their fluctuations limit utility, particularly if day of week
collection standards are not specified.
Our data highlight patient and facility differences across
higher (versus lower) UF rates that may have unintended
consequences. We showed that patients with higher UF
rates are more likely to be women, nonblack, and Hispanic
and have lower body weight. Facilities with higher UF rate
measure scores (less favorable) were more likely to be
located in the western United States compared with
facilities with lower scores. Lower proportions of black
patients, higher proportions of Hispanic patients, and body
size differences likely account for these geographic differ-
ences (Supplemental Table 5). Such discrepancies highlight
the importance of additional investigation of the UF rate
and outcome association across categories of race, sex, and
body size.
Related, both proposed measures apply a universal UF
rate threshold of 13 ml/h per kilogram. This one size fits all
approach assumes that all patients experience risk at the
same UF rate threshold. A post hoc analysis of the Hemo-
dialysis Study showed that UF rate risk rises steeply be-
tween 10 and 13 ml/h per kilogram, with the greatest risk
6 Clinical Journal of the American Society of Nephrology
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at rates .13 ml/h per kilogram. This risk threshold varied
by subgroups: patients with heart failure had a higher
mortality risk at lower UF rates (10–13 ml/h per kilo-
gram), whereas patients without heart failure did not
(12). In this study, we reported that almost 50% of patients
with heart failure had UF rates .10 ml/h per kilogram.
We found that over one third of other hemodynamically
vulnerable subpopulations, such as patients with low
pre–HD BP and intradialytic hypotension, had monthly
UF rates .10 ml/h per kilogram. The proposed thresh-
old might leave many high–risk patients inadequately
protected.
Selection criteria designation is critical to measure de-
velopment. The KCQA and the CMS measures differ in
numerator specifications. The KCQA measure includes a
TT caveat: the numerator includes patients with UF rates
$13 ml/h per kilogram and TTs,240 minutes. The
denominator encompasses all facility patients meeting se-
lection criteria regardless of TT. The CMS measure does
not have a numerator TT limitation. This distinction re-
sults in notable differences in the percentages of facility
patients above UF rate thresholds: 22.3% for the CMS mea-
sure versus 17.4% for the KCQA measure (January of
2012). Recent data show an association between higher
UF rates and mortality among patients with longer HD
times (J. Bragg-Gresham, et al., unpublished data). The
KCQA measure does not facilitate UF rate–related harm
reduction among patients with TTs.4 hours. The KCQA
proponents propose that the TT caveat addresses patient
preference for shorter TT. It also gives facilities two ways
to comply with the measure: by lowering UF rates to ,13
ml/h per kilogram or increasing TT to $4 hours. Addi-
tionally, the TT restriction minimizes the KCQA measure’s
effect on facility operations. In our analyses, facilities
Figure 3. | Illustration of treatment time (TT) extension calculation for a single patient with varying prescribed ultrafiltration (UF) rates over
1 month (13 treatments). The black circles represent the prescribed UF rates on the basis of observed interdialytic weight gains and prescribed
TTswithout application of aUF rate threshold. The white circles represent the updatedUF rates after the application of aUF rate threshold of 13
ml/h per kilogram under the constraint of a 4-hour TT maximum. The striped bars represent the prescribed TT (180 minutes) during the month
assessed. The black bars represent the calculated amount of additional TT needed to reduce UF rates to ,13 ml/h per kilogram without ex-
tending total TT beyond 4 hours. For treatments with a prescribed UF rate of ,13 ml/h per kilogram, no additional TTwas assigned, and no
change to the UF rate was made. For treatments with a prescribed UF rate of$13 ml/h per kilogram, the additional TT (in minutes) needed to
achieve the UF rate,13 ml/h per kilogram was calculated as follows: ([predialysis weight from current treatment2 postdialysis weight from
previous treatment (milliliters)]/[postdialysis weight from previous treatment (kilograms)312.9])3602 prescribed TT (minutes). Total TTwas
capped at 4 hours per treatment, such that the UF rate remained$13 ml/h per kilogram for treatments in which UF rate reduction to rates,13
ml/h per kilogramwould result in TTextension beyond 4 hours. Additional patient TTs were then summed for the month. Detailed methods for
estimation of TT extension are described in Supplemental Table 2. HD, hemodialysis.
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treating .100 patients required 33 h/wk of extra treat-
ment to lower UF rates to ,13 ml/h per kilogram in the
setting of a 4-hour TT maximum. When the 4-hour TT cap
was omitted, the additional weekly facility treatment
hours tripled. Increased TT is associated with substantial
costs related to staffing, supplies, water, and utilities. Fur-
thermore, added TT has implications beyond cost. Extend-
ing HD treatments would have consequences for other
patients who would be subject to fluctuating start times
when earlier patients required longer treatments. In this
regard, the 4-hour TT carve out might minimize disrup-
tions to other patients.
Titrated HD treatments pose substantial patient and
facility challenges, suggesting that IDWG reduction may
represent the most feasible UF rate reduction approach.
Intensive dietary salt counseling has been shown to reduce
weight gains (17,18). Nutritional programs that teach salt
(and fluid) restriction in ways that are relatable to and
Figure 4. | Weekly required additional facility treatment time (TT) for a maximum run time of 4 hours with the application of a 13-ml/h per
kilogram ultrafiltration (UF) rate threshold stratified by facility size. The additional TT required to lower prescribed UF rates to,13 ml/h per
kilogram was computed at the facility level and stratified by facility size. Total TTwas capped at 4 hours per the Kidney Care Quality Alliance
(KCQA) specifications. For these analyses, prescribed UF rate (milliliters per hour per kilogram) was calculated using the formula (predialysis
weight from current treatment 2 postdialysis weight from previous treatment [milliliters])/prescribed TT (hours)/postdialysis weight from
previous treatment (kilograms). For treatments with a prescribed UF rate of ,13 ml/h per kilogram, no additional TT was assigned. For
treatmentswith a prescribedUFrate of$13ml/h per kilogram, the additional TT (minutes) needed to achieve theUFrate,13ml/h per kilogram
was calculated as follows: ([predialysis weight from current treatment2 postdialysis weight from previous treatment (milliliters)]/[postdialysis
weight from previous treatment (kilograms)312.9])3602 prescribed TT (minutes). Total TTwas capped at 4 hours per treatment, such that the
UF rate remained at $13 ml/h per kilogram for treatments in which UF rate reduction to rates ,13 ml/h per kilogram would result in TT ex-
tension beyond 4 hours. Additional patient TTs were then summed for the month at the patient and then facility levels. Detailed methods for
estimation of TT extension are described in Supplemental Table 2. CMS, Centers for Medicare and Medicaid Services.
Table 4. Proportion of patients with ultrafiltration rates ‡13 ml/h per kilogram after application of varied hypothetical treatment time
extension paradigms
Facility TT Change
UF Rate $13 ml/h per kg
before TT Extension,
% (no. of patients)
UF Rate $13 ml/h per kg
after TT Extension,
% (no. of patients)
Extend TT by 15 min if TT is ,240 min 19.4 (20,152) 15.8. (16,418)
Extend TT by 30 min if TT is ,240 min 19.4 (20,152) 12.8 (13,332)
Extend TT to 240 min if TT is ,240 min 19.4 (20,152) 11.0 (11,395)
Extend TT long enough to achieve
UF rate ,13 ml/h per kg if TT is ,240 min
19.4 (20,152) 3.1 (3199)
Extend TT long enough to achieve
UF rate ,13 ml/h per kg regardless of TT
19.4 (20,152) 0.0 (0)
Estimation of TT extension was on the basis of the monthly Kidney Care Quality Alliance cohort from January of 2012 (n=103,850).
TT, treatment time; UF, ultrafiltration.
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achievable by patients are needed. However, it is unlikely
that dietary restrictions on their own will be enough to
lower UF rates for all patients, and facilities will need to
adopt a more flexible approach to dialysis provision. An-
other approach to weight gain reduction is dialysate so-
dium adjustment, but outcome data are mixed (19,20).
Finally, it is plausible that UF rate threshold implementa-
tion will incentivize some patients to curb excessive salt
and fluid intake to avoid longer treatments, offsetting fa-
cility burden.
Overall, our data highlight the challenges, uncertainties,
and potential consequences of an ESRDQIP UF rate measure.
Incorporation of exceptions and flexibility not previously
applied to other QIP measures might optimize the UF rate
measure. For example, should facilities be exempted from
financial penalties if patients decline longer treatments and
the facility documents good faith efforts at IDWG reduction?
Would it be feasible to tie reimbursement to dialysis time
rather than the current fixed reimbursement per treatment?
How can reimbursement policies be altered to incentivize
home-based therapies that allow formore frequent treatments
with more gradual UF? How should patient preferences be
incorporated intomeasure implementation? The proposedUF
rate QIP measure is a critical first step in codifying optimal
volume management into high–quality dialysis care, but the
challenges of volume management, particularly given the ab-
sence of objective measures, introduce complexities that
should be recognized.
Our results must be considered in the context of study
limitations. First, most importantly, we considered data
from a single LDO. The facility–level UF rate patterns that
we observed may not be representative of other dialysis
organizations’ facility patterns. UF rate patterns may vary
under different clinical protocols. Second, our study is de-
scriptive. Conclusions about differences in the UF rate and
outcome association across subpopulations cannot be
drawn. Third, we estimated the amount of additional fa-
cility TT that would be required with UF rate threshold
implementation. In these calculations, we used prescribed
rather than delivered UF rates and assumed that treat-
ments for all patients with elevated UF rates would be
extended. We were unable to account for patient refusal
of TT extension or potential effects from more intensive
dietary counseling. Fourth, we used UF rate measure def-
initions and selection criteria according to the CMS and
the KCQA specifications. Results cannot be generalized
to excluded populations, such as children and patients
from facilities with ,11 patients.
In conclusion, our findings suggest a need for reconsid-
eration of the proposed UF rate measure definition and
additional research regarding the UF rate to outcome
association in key subpopulations. Before adoption of UF
rate as a dialysis facility quality indicator, prospective
studies of patient and facility consequences of UF rate
threshold implementation as well as pilot studies of the
proposed rule are needed.
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